ABBISKO-B(02256) intends to distribute shares at HK$12.18 per share, raising approximately HK$5.17 billion net.

date
08:33 21/04/2026
avatar
GMT Eight
Honor-B (02256) announced that on April 21, 2026, the company plans to issue 42.9 million shares at a price of HK$12.18 per share through a placement agent, with net proceeds of approximately HK$517 million. Approximately 90% of the proceeds will be used for research and development of innovative oncology and non-oncology candidate drugs, advancement of international multicenter clinical trials, and potential commercial activities; and about 10% for general corporate purposes.
ABBISKO-B (02256) announced that on April 21, 2026, the company plans to issue 42.9 million shares through a placement agent at a price of HK$12.18 per share, raising approximately HK$517 million in net proceeds. Around 90% of the funds will be used for research and development of innovative cancer and non-cancer drug candidates, advancing international multicenter clinical trials, and potential commercial activities; while approximately 10% will be used for general and corporate purposes.